Acute respiratory distress syndrome (ARDS) secondary to viral pneumonias, predominantly COVID-19 but also influenza and adenovirus, remains a major ICU mortality driver, with rates exceeding 40%. Chronic high-altitude adaptation (≥ 2,500 m) modifies human pulmonary physiology through hypoxia-inducible factor (HIF-1α/2α) stabilization, ACE2 downregulation, enhanced capillary recruitment, and anti-inflammatory shifts, potentially reducing ARDS severity. Across published observational studies, findings remain heterogeneous; however, several cohorts have reported lower mortality at moderate-to-high altitude (approximately 30–50% in some reports), along with proposed altitude-appropriate SpO₂ targets (89–93%) and alternative interpretations of oxygenation indices (e.g., barometric pressure–adjusted P/F ratios). Protection is strongest in younger, comorbidity-free patients, but attenuates in diabetics/hypertensives. In this perspective, we critically examine the evidence on how altitude may influence the clinical course and survival of critically ill patients, exploring potential pulmonary adaptive mechanisms and reflecting on their implications for monitoring and management in intensive care units.
Osborne et al. (Wed,) studied this question.